Neurons must maintain a supply of neurotransmitter in their presynaptic terminals to fill synaptic vesicles. GABA is taken up into inhibitory terminals by transporters or is synthesized from glutamate by glutamic acid decarboxylase. Here we report that glutamate transporters supply GABAergic terminals in the hippocampus with glutamate, which is then used to synthesize GABA for filling synaptic vesicles. Glutamate transporter antagonists reduced IPSC and miniature IPSC (mIPSC) amplitudes, consistent with a reduction in the amount of GABA packaged into each synaptic vesicle. This reduction occurred rapidly and independently of synaptic activity, suggesting that modulation of vesicular GABA content does not require vesicle release and refilling. Raising extracellular glutamate levels increased mIPSC amplitudes by enhancing glutamate uptake and, consequently, GABA synthesis. These results indicate that neuronal glutamate transporters strengthen inhibitory synapses in response to extracellular glutamate. This modulation appears to occur under normal conditions and may constitute a negative feedback mechanism to combat hyperexcitability.
Introduction
Glutamate is an essential component of synaptic transmission in the CNS, both at excitatory synapses, where it is the neurotransmitter, and at inhibitory synapses, where it serves as the substrate for GABA synthesis. In excitatory neurons, glutamate is synthesized either from glutamine or from glucose metabolites. Both pathways rely on astrocytes, which supply neurons with essential substrates (for review, see Hertz et al., 1999) . Glutamate is also taken up into excitatory presynaptic terminals by high-affinity transporters (for review, see Danbolt, 2001 ). In inhibitory neurons, all GABA, except that taken up through transporters, is synthesized by decarboxylation of glutamate by glutamic acid decarboxylase (GAD; for review, see Martin and Tobin, 2000) . It is not known whether glutamate metabolism in inhibitory terminals mirrors that in excitatory terminals, although it has been proposed that glutamate may be taken up into inhibitory terminals by presynaptic transporters (Rothstein et al., 1994; Sepkuty et al., 2002) .
High-affinity glutamate transporters function primarily to maintain a low concentration of glutamate in the extracellular space. Although some subtypes [glutamate transporter 1 (GLT-1) and glutamate-aspartate transporter] are localized predominantly to astrocytes, others [excitatory amino acid carrier 1 (EAAC1) and excitatory amino acid transporter 4] are expressed mostly by neurons (Rothstein et al., 1994) . Both glial and neuronal transporters may be localized to play specific homeostatic roles, although a lack of selective inhibitors (except for GLT-1) has hindered investigation of unique physiological roles for these transporters. Perisynaptic transporters may be positioned to prevent excitotoxicity (Rothstein et al., 1996) , to limit diffusion of glutamate between excitatory synapses (Asztely et al., 1997; Lozovaya et al., 1999; Carter and Regehr, 2000; Diamond, 2001; Arnth-Jensen et al., 2002) , or to supply the terminal with neurotransmitter (Gundersen et al., 1993) . Transporters used by excitatory terminals have not been identified but may be a GLT-1-like subtype (Danbolt, 2001; Chen et al., 2002) . Anatomical data indicate that the neuronal subtype EAAC1 colocalizes with GAD (Conti et al., 1998) and is located at inhibitory terminals (Rothstein et al., 1994; He et al., 2000) . Reducing expression of EAAC1 is associated with a decrease in both tissue GABA levels and de novo synthesis from glutamate, which may lead to neuronal hyperexcitability and epilepsy (Sepkuty et al., 2002) .
We show here that presynaptic glutamate transporters are involved in the bidirectional regulation of inhibitory synaptic transmission. Inhibiting neuronal glutamate transporters reduced GABA A receptor (GABA A R)-mediated IPSCs and miniature IPSCs (mIPSCs), suggesting that GABA synthesis and, consequently, vesicular filling were reduced. These effects did not depend on astrocytic glutamate metabolism. They also occurred independently of synaptic activity, suggesting that transmitter concentration can be modulated in vesicles that are ready to be released. In addition, enhancing glutamate uptake increased the amplitude of miniature IPSCs. The bidirectional regulation of GABAergic transmission was prevented by an inhibitor of GAD, verifying that the uptake-dependent effects required GABA synthesis. Our findings that glutamate transporters on inhibitory terminals contribute to GABA release suggest that a compensatory or protective mechanism allows extracellular glutamate to strengthen inhibitory synapses.
Materials and Methods
Electrophysiology. Whole-cell patch-clamp recordings from CA1 pyramidal neurons were made in transverse hippocampal slices (400 m thick) made from postnatal day 10 -14 d rats as described previously (Sakmann and Stuart, 1995) . Slices were stored in and perfused with a solution containing (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl 2 , 1.3 MgCl 2 , 1 NaH 2 PO 4 , 26.2 NaHCO 3 , and 11 glucose, bubbled with 95% O 2 and 5% CO 2 at room temperature. All solutions also contained 10 M 6,7-dinitroquinoxaline-2,3-dione (DNQX) and 5 M MK-801 (dizocilpine maleate) to block glutamatergic responses (20 M DNQX was used when exogenous glutamate was applied). Patch pipettes (resistance, 2-4 M⍀) were filled with (in mM): 130 CsCl, 10 EGTA, 10 HEPES, 2 Mg-ATP, 0.2 Na-GTP, and 1 QX-314 (lidocaine N-ethyl bromide), titrated to pH 7.4 with CsOH. Using an upright fixed stage microscope (Zeiss, Thornwood, NY), pyramidal neurons were identified under video observation using infrared differential interference contrast imaging. Unless indicated otherwise (see Figs. 4C, 5D ), voltage-clamp recordings (V hold ϭ Ϫ60 mV, uncorrected for junction potential) were made at room temperature using an Axopatch 1D amplifier (Axon Instruments); currents were filtered at 2 kHz, sampled at 5 kHz, and digitally stored for off-line analysis (IGOR Pro software). Access resistance was monitored throughout the experiment, and data were discarded when Ͼ10% change occurred. IPSCs were evoked at 8 -15 sec intervals with a bipolar stainless steel electrode placed in the stratum oriens (constant current stimulation, 25-150 A; 100 sec duration). When required, D,L-threo-␤-hydroxyaspartic acid (THA, 300 M) and dihydrokainic acid (DHK, 300 M; Ocean Produce International) were dissolved in the recording solutions just before the experiment; D,L-threo-␤-benzyloxyaspartic acid (TBOA, 30 M) was diluted from a stock solution. Sucrose (500 mM) and GABA (10 M) were added to the control solution and were pressure-applied (2-3 sec puffs, 4 -5 psi) through a patch pipette. When effects of THA on puffed GABA responses were tested, THA was included in the perfusion and pipette solutions. In hyperosmotic stimulation experiments, 1 min was allowed between applications to ensure refilling of the vesicular pool, and responses were quantitated by integrating the current over the duration of the sucrose application. For studies involving inhibition of GAD or glutamine synthetase, mercaptopropionic acid (MPA, 250 M) or methionine sulfoximine (MSO, 1.5 mM) was included in solutions used for storage (3-7 hr before recording) and perfusion of slices.
mIPSC recording and analysis. Electrically evoked mIPSCs were obtained as described above, except that calcium in the extracellular solution was replaced with strontium, giving rise to numerous asynchronous events after each stimulus (Goda and Stevens, 1994) . Stimuli were delivered every 8 -10 sec, and events were collected in the 718 msec after each stimulus, excluding the initial 100 msec. Raw traces were differentiated and smoothed; events exceeding a slope threshold (chosen to detect even the smallest and slowest events) were then visually examined. Only single events occurring from a level baseline were selected for analysis. Responses to 60 -70 stimuli, resulting in ϳ200 events, were elicited in each condition in each cell. When drug effects were measured, 5 min of wash-in was allowed before mIPSCs were collected. To compare between cells, individual event amplitudes in each cell were normalized to the mean amplitude in a control. Decay time constants were estimated by fitting a single exponential to the decay phase of the averaged mIPSC in each cell.
Unless indicated otherwise, data are expressed as mean Ϯ SD, and p values were derived from paired t tests, with significance concluded at p Ͻ 0.05. For pooled mIPSC amplitudes, which were not normally distributed, the Mann-Whitney U test was used. In graphs illustrating responses over time from a collection of experiments (see Figs. 1C, 3D ) and in cumulative probability histograms (see , error bars indicate SEM.
Results

Glutamate transporter blockade reduces electrically evoked IPSCs
Inhibitory interneurons are abundant in stratum oriens (SO) of area CA1, where distinct subtypes make either axosomatic or axodendritic synapses onto excitatory pyramidal neurons (McBain and Fisahn, 2001 ). In juvenile hippocampal slices (postnatal days 10 -14), electrical stimulation in SO elicited monosynaptic GABA A R-mediated IPSCs, which were recorded under whole-cell voltage-clamp conditions (V hold ϭ Ϫ60 mV) in the presence of glutamate receptor antagonists (see Materials and Methods). Inward IPSCs (attributable to symmetrical chloride concentrations) could be blocked completely by SR95531 (gabazine) (10 M), a selective GABA A R antagonist (Fig. 1 A) . To examine the effects of glutamate uptake on IPSCs, we applied THA (300 M), a competitive inhibitor of both neuronal and astrocytic glutamate transporters (Arriza et al., 1994) . THA (300 M) does not completely block glutamate uptake in hippocampal slices (Bergles and Jahr, 1997) , because it is also transported, thereby reducing its effective concentration. THA reduced evoked IPSC amplitudes to 74 Ϯ 22% of control ( p Ͻ 0.001; n ϭ 16 cells; Fig.  1 B,C,H ) ; this effect recovered only partially on washout. A nontransported inhibitor, TBOA (30 M; Shimamoto et al., 1998) , caused a similar reduction in (and incomplete recovery of) IPSC amplitude (to 71 Ϯ 10% of control; p ϭ 0.005; n ϭ 4 cells; Fig.  1 D,H ) , suggesting that THA did not exert its effect intracellularly (e.g., by inhibiting vesicular transporters). To test whether the effects of glutamate transporter inhibition on IPSCs were mediated by the GABA synthetic pathway, THA was applied to slices that had been preincubated for 3-7 hr with the GAD inhibitor MPA (250 M; Lamar, 1970) . IPSC amplitudes were gradually reduced after application of MPA without reaching a plateau in 30 min (data not shown); after several hours of preincubation with MPA, stronger stimuli were required to evoke IPSCs that were smaller on average than those of controls (Ϫ380 Ϯ 177 pA in MPA vs Ϫ711 Ϯ 447 pA). In MPA-treated slices, THA had no significant effect on IPSC amplitudes (110 Ϯ 20% of control; p ϭ 0.17; n ϭ 5; Fig. 1 E,H ), suggesting that transported glutamate acts as a substrate for GABA synthesis.
Glutamate taken up by astrocytes may be converted to glutamine and returned to neurons, a cycle requiring the glialspecific enzyme glutamine synthetase (Martinez-Hernandez et al., 1977) . It is possible that THA, a blocker of astrocytic and neuronal glutamate transporters, reduces IPSC amplitudes by disrupting this intermediary metabolism. We tested this possibility with MSO, an inhibitor of glutamine synthetase (Sellinger, 1967) . MSO (1.5 mM) prevents conversion of glutamate to glutamine, thereby trapping glutamate in glial cells and decreasing glutamate levels in synaptic terminals twofold (Laake et al., 1995) . In slices that had been preincubated for 3-7 hr with 1.5 mM MSO, field EPSPs were reduced by 35% compared with responses elicited under identical conditions in control slices (control, 0.51 Ϯ 0.21 mV; n ϭ 12; MSO, 0.33 Ϯ 0.16 mV; n ϭ 12; p ϭ 0.02, unpaired t test), indicating that glutamate metabolism was compromised. In MSO-treated slices, however, THA still reduced IPSC amplitudes to 71 Ϯ 17% of control ( p ϭ 0.03; n ϭ 7 cells; Fig. 1 F,H ), indicating that glutamate transporter antagonists do not reduce IPSCs through actions on astrocytic glutamate uptake.
Interneurons in stratum radiatum (SR) express higher levels of the GABA transporter GAT-1 than interneurons in SO (Engel et al., 1998) and therefore may rely less than SO interneurons on GABA synthesis to fill synaptic vesicles. Nonetheless, THA also reduced IPSCs elicited by SR stimulation (55 Ϯ 27% of control; p ϭ 0.014; n ϭ 5 cells; Fig. 1G ,H ), indicating that a role for presynaptic glutamate uptake is not unique to SO interneurons. Responses in all subsequent experiments were elicited by stimulation in SO.
These results suggest that glutamate uptake into inhibitory synaptic terminals is an important source of GABA for filling synaptic vesicles. If vesicles remain filled to a "set point" until being released, one would expect that the effects of transporter blockade would not be evident until the pool of filled vesicles was released and recycled. Evidence suggests, however, that the vesicular transmitter concentration reflects a dynamic equilibrium between the vesicle and the synaptic terminal (Williams, 1997) , allowing transmitter levels in vesicles to be modulated before release. To distinguish between these possibilities, in a separate set of experiments stimulation was suspended for the first 5 min of THA application to test whether the effect of THA required synaptic activity. When stimulation was resumed, a similar reduction in IPSC amplitude was observed (70 Ϯ 16% of control; p ϭ 0.03; n ϭ 5 cells; Fig. 1C ) as when stimulation was not interrupted, suggesting that the effects of blocking glutamate transporters do not require release and subsequent recycling of synaptic vesicles.
THA does not affect release probability or postsynaptic GABA A Rs Activation of presynaptic metabotropic glutamate receptors (mGluRs) inhibits GABA release at some synapses (Desai et al., 1994; Gereau and Conn, 1995; Mitchell and Silver, 2000) ; blocking glutamate transporters enhances mGluR activation at both excitatory and inhibitory synapses (Fitzsimonds and Dichter, 1996; Brasnjo and Otis, 2001; Reichelt and Knopfel, 2002) . To test whether the decreased IPSC amplitude in the presence of THA involved mGluR activation, THA was applied in the presence of group I and II and group III mGluR antagonists [(RS)-␣-methyl-4-carboxyphenylglycine (MCPG), 500 M; and (RS)-␣-cyclopropyl-4-phosphonophenylglycine (CPPG), 200 M, respectively]. THA nonetheless reduced the IPSC amplitude (to 81 Ϯ 3% of control; p ϭ 0.02; n ϭ 4; Fig. 2 A) . The effect in the presence of mGluR antagonists was not significantly different from that in their absence ( p ϭ 0.5, unpaired t test; Fig. 2 B) , suggesting that mGluRs do not mediate the IPSC reduction. THA affected neither paired pulse depression (observed in 2.5 mM calcium: 105 Ϯ 13% of control; n ϭ 6; p ϭ 0.37) nor paired pulse facilitation (observed in 1 mM external calcium: 99 Ϯ 26% of control; n ϭ 5; p ϭ 0.99) of IPSCs (Fig. 2C,D) , suggesting that the reduction of IPSC amplitude was not attributable to a change in release probability. Moreover, THA did not reduce the response to exogenously applied GABA (puff responses in THA were 102 Ϯ 9% of control; p ϭ 0.9; n ϭ 3; Fig. 2 E,F ) , indicating that the drug did not affect postsynaptic GABA A receptors.
THA reduces hyperosmotically evoked IPSCs
The above results suggest that THA acts presynaptically to reduce IPSC amplitude without altering release probability. If glutamate uptake contributes to the process by which presynaptic vesicles are filled with GABA, one would predict that blocking transporters with THA would reduce vesicular filling and diminish the postsynaptic response to release of the entire pool of synaptic vesicles. Application of hyperosmolar extracellular solution elicits release of the "readily releasable pool" (RRP) of vesicles through mechanisms that are independent of action potentials and calcium influx (Rosenmund and Stevens, 1996) . Puff application of control extracellular solution supplemented with 500 mM sucrose evoked a barrage of synaptic events, giving rise to a postsynaptic response that could be blocked by the GABA A R antagonist SR95531 (Fig. 3A) . The sucrose-evoked response decayed back toward baseline during the puff, and immediately subsequent puffs elicited greatly diminished responses (Fig. 3B) , suggesting that most of the RRP was depleted during a single application. The depletion gradually recovered such that consistent responses could be elicited at 1 min intervals (Fig. 3D) . THA reduced the postsynaptic response to hyperosmotic stimulation (to 76 Ϯ 9% of control; n ϭ 9; p Ͻ 0.0001; Fig. 3C,D) , consistent with a reduction in the total amount of GABA packaged into the vesicles composing the RRP. The onset and extent of the effect of THA on electrically and sucrose-evoked IPSCs were similar (compare Figs. 1C, 3D ), even though each sucrose application depleted the RRP, and electrical stimulation did not. These results, together with those showing that the effect of THA on IPSCs is not activity-dependent (Fig. 1C) , are consistent with the idea that modulation by glutamate uptake of vesicular GABA content does not require release and recycling of synaptic vesicles.
Blocking glutamate uptake reduces miniature IPSC amplitudes
Although the results presented thus far are consistent with blockade of glutamate uptake reducing GABA synthesis and, consequently, the amount of transmitter packaged into each vesicle, the effects of THA also could be explained by a reduction in the total number of synaptic vesicles available for release. In other systems, manipulations that increase or decrease vesicle filling cause commensurate changes in the amplitude of miniature synaptic events (Song et al., 1997; Pothos et al., 1998; Van der Kloot et al., 2000) , suggesting that vesicles need not contain a prescribed amount of transmitter to be released. Moreover, mIPSCs recorded from hippocampal pyramidal cells in rats in which EAAC1 had been knocked down with chronic exposure to antisense oligonucleotides were smaller than those recorded in control animals (Sepkuty et al., 2002) . Conversely, knocking out the synaptically localized GAD isoform GAD65 did not affect amplitude but decreased the frequency of GABA A R-mediated mIPSCs (Tian et al., 1999) , possibly because only the "full" vesicles were released. To distinguish between these alternatives, we tested the effects of glutamate transporter blockade on postsynaptic responses to the release of single vesicles. Extracellular calcium was replaced with strontium to desynchronize electrically evoked release and thereby to resolve postsynaptic responses to individual release events occurring at stimulated synapses (Goda and Stevens, 1994) (Fig. 4 A) . In some cells, relatively high spontaneous release rates made it difficult to ensure that all events occurring within 700 msec of stimulation arose at stimulated synapses (the first 100 msec of the response, comprising primarily the synchronous IPSC, was excluded). However, the size and shape of presumptive evoked events in these cells, as well as the effects of various experimental manipulations described below, were indistinguishable from those obtained in cells with lower spontaneous activity, so the results were pooled, and the events will be referred to as mIPSCs. THA (300 M) reduced the mean mIPSC amplitudes obtained in 11 cells from 32 Ϯ 5 to 28 Ϯ 3 pA, or by ϳ13% (Fig. 4 B, inset) . Individual mIPSCs normalized to the mean for each cell were then pooled, and cumulative probability histograms were generated, demonstrating a significant shift in the amplitude distribution ( p Ͻ 0.0001, Mann-Whitney U test; n ϭ 1491 in control and 1624 in THA; Fig. 4 B) . Using identical selection criteria, similar numbers of events were obtained in each condition, suggesting that a change in mIPSC frequency did not occur in THA. The decay time constants of the average mIPSCs from individual cells were not altered by THA (24.7 Ϯ 9.6 msec in control vs 23.8 Ϯ 4.8 msec in THA; p ϭ 0.8; n ϭ 11 cells), indicating that altered membrane properties did not account for the amplitude changes.
Neurotransmitter uptake and synthesis involve a series of temperature-dependent enzymatic reactions. The experiments presented thus far were performed at room temperature; at physiological temperatures, the increased capacity of other processes may reduce the impact of glutamate uptake on GABA synthesis, even though glutamate uptake itself is steeply temperaturedependent (Wadiche and Kavanaugh, 1998) . At 34°C, however, THA reduced mIPSC amplitudes to 84 Ϯ 8% of control in five cells (pooled data, p Ͻ 0.0001; n ϭ 909 in control and 958 in THA; Fig. 4C ), similar to the effects at room temperature, suggesting that glutamate uptake contributes to GABA synthesis at more physiological temperatures. Consistent with recent studies using molecular approaches to knock down neuronal glutamate transporters (Sepkuty et al., 2002) , these results suggest that reducing glutamate uptake leads to a decrease in intraterminal glutamate levels and, as a result, a lower concentration of GABA in synaptic vesicles.
If filling of synaptic vesicles depends in part on newly synthesized GABA, and glutamate transporters provide the substrate for GABA synthesis, one would expect that incubation with MPA, which reduced IPSC amplitudes, would also reduce mIPSC amplitudes. The mean amplitude of pooled mIPSCs recorded in nine cells that had been preincubated with the GAD inhibitor MPA was 16% smaller than the mean from 19 pooled controls, and their distribution was significantly changed ( p Ͻ 0.0001, Mann-Whitney U test; n ϭ 3483 for control and 1758 for MPA; data not shown).
Exogenous glutamate application increases mIPSC amplitudes
The data presented in Figure 4 indicate that reducing glutamate uptake into inhibitory terminals reduces GABA synthesis and, consequently, the amount of GABA released from synaptic vesicles. These results raise the possibility that increasing glutamate uptake may enhance GABAergic transmission, provided that postsynaptic GABA A Rs are not normally saturated during a synaptic event (Frerking et al., 1995; Nusser et al., 1997; Hajos et al., 2000; Perrais and Ropert, 2000) . Such a mechanism could increase inhibition and thereby offer protection against hyperexcitability associated with pathological increases in extracellular glutamate levels. To test this idea, glutamate was added to the superfusion solution while mIPSCs were evoked in the presence of Sr 2ϩ (Fig. 5) . Addition of 100 M glutamate increased mean mIPSC amplitudes in 10 cells to 120 Ϯ 25% of control (pooled data, p Ͻ 0.0001, Mann-Whitney U test; n ϭ 1990 in control and 1975 in glutamate; Fig. 5A ). A higher concentration (500 M) increased mIPSC amplitudes in nine cells even more (156 Ϯ 41% of control; pooled data, p Ͻ 0.0001; n ϭ 1493 in control and 1477 in glutamate; Fig. 5A ). These increases appeared to reflect enhanced GABA synthesis, because 500 M glutamate exerted a much smaller effect in slices preincubated with 250 M MPA (mean mIPSCs from 10 cells, 117 Ϯ 27% of control; Fig. 5B) . Moreover, the effect of 100 M glutamate was abolished when it was applied together with THA (300 M) in five cells (300 M; 102 Ϯ 23% of control; pooled data, p ϭ 0.95; n ϭ 1088 in control and 1418 in glutamate plus THA; Fig. 5C ). Applied alone, glutamate (100 M) also caused an amplitude increase in mIPSCs (gray) and in the same cell after calcium was replaced with strontium (black). In the presence of strontium, a diminished synchronous component of the response was followed by asynchronously released events, which were collected and pooled for each cell under each experimental condition. B, mIPSC amplitudes in control (strontium) solution (gray symbols; n ϭ 1624 events) and in the additional presence of 300 M THA (black symbols; n ϭ 1491 events). Events in each of 11 cells were normalized (norm) to the mean mIPSC amplitude in control, and cumulative probability histograms were placed into 25 equal bins (p between 0 and 1), allowing events in different cells to be pooled. Error bars indicate cell-to-cell variability (SEM) of the normalized histograms. Inset, Average mIPSC waveforms from a representative cell in control solution (gray) and in the presence of THA (black). C, mIPSC amplitudes in control (strontium) solution (gray symbols; n ϭ 909 events) and in the additional presence of 300 M THA (black symbols; n ϭ 958 events) recorded at 34°C. Inset, Average mIPSC waveforms from a representative cell in control solution (gray) and in the presence of THA (black).
recorded at 34°C (116 Ϯ 22% of control in six cells; pooled data, p Ͻ 0.0001; n ϭ 973 in control and 1177 in glutamate; Fig. 5D ).
Presynaptic uptake does not exhibit GLT-1 pharmacology
A selective blocker of GLT-1, DHK (Arriza et al., 1994) inhibits glutamate uptake into excitatory synaptic terminals (Gundersen et al., 1993; Danbolt, 2001) . Recently, a splice variant of GLT-1 that may be localized presynaptically on neurons was identified (Chen et al., 2002) , suggesting a role in supplying excitatory terminals with glutamate. We used DHK to test whether the presynaptic transporter on inhibitory terminals is GLT-1-like. If it were, DHK would be expected to exert effects similar to those of THA. Alternatively, if DHK blocked only astrocytic transporters, it might be expected to raise extracellular glutamate (Muñoz et al., 1987) and to mimic exogenous glutamate.
The effects of DHK (300 M) on evoked IPSCs were complex (data not shown), possibly confounded by effects on release probability through activation of presynaptic kainate receptors (Kamboj et al., 1992; Rodriguez-Moreno et al., 1997) . Because mIPSC amplitudes should not be affected by changes in release probability, we examined the effect of DHK on mIPSCs. DHK increased mIPSC amplitudes to 132 Ϯ 20% of control in eight cells (pooled data, p Ͻ 0.0001; n ϭ 1455 in control and 1409 in DHK; Fig. 6 A) . The effect of DHK on mIPSC amplitudes was attributable to increased GABA synthesis, because no changes were observed in slices preincubated in 250 M MPA (100 Ϯ 9% of control in five cells; pooled data, p ϭ 0.6; n ϭ 790 in control and 1096 in DHK; Fig. 6 B) . The striking difference between the effects of DHK and THA indicates that the presynaptic transporter on inhibitory terminals is not DHK-sensitive and therefore not a GLT-1 isoform. Furthermore, the effect of DHK is consistent with the hypothesis that elevating extracellular glutamate levels by blocking glial transport (Muñoz et al., 1987) enhances glutamate uptake into neurons and, consequently, increases GABA synthesis. These opposing effects of THA and DHK on mIPSC amplitudes (Figs. 4, 6 ) suggest that alterations of glutamate uptake into inhibitory presynaptic terminals may downregulate or upregulate the amount of GABA contained in synaptic vesicles and thereby regulate inhibitory synaptic strength.
Discussion
The findings presented here indicate that glutamate transporters regulate the synaptic pool of GABA in hippocampal CA1 interneurons. Reducing glutamate uptake diminished evoked IPSCs and mIPSCs without affecting postsynaptic receptors, suggesting that vesicular GABA content was reduced. These effects required GABA synthesis but not glial glutamate metabolism, suggesting that glutamate is taken up directly into inhibitory terminals and converted to GABA, which is then packaged into synaptic vesi-4 of 500 M glutamate on mIPSC amplitude. The data for 500 M glutamate from A (open circles) are included for comparison. Inset, Average mIPSC waveforms from a representative cell preincubated in MPA in control solution (gray) and in the presence of 500 M glutamate (black). C, Three hundred micromolar THA blocked the effect of glutamate on mIPSCs. mIPSCs recorded during coapplication of 300 M THA and 100 M glutamate (black symbols; n ϭ 1418 events) were not different compared with control (gray symbols; n ϭ 1088 events). Inset, Average mIPSC waveforms from a representative cell in control solution (gray) and in the presence of 300 M THA and 100 M glutamate (black). D, Recorded at 34°C, addition of 100 M glutamate (black symbols; n ϭ 1177 events) increased mIPSC amplitude compared with control (gray symbols; n ϭ 973 events). Inset, Average mIPSC waveforms from a representative cell in control solution (gray) and in the presence of 100 M glutamate (black). norm, Normalized. cles. Enhancement of mIPSCs by exogenous glutamate also required glutamate uptake and GABA synthesis. Previous work has shown that modulating GABA metabolism influences mIPSC amplitudes (Engel et al., 2001) ; our data point to glutamate uptake as an endogenous mechanism for bidirectional modulation of GABA synthesis and, consequently, inhibitory synaptic strength. GABA synthesis in vivo is decreased after knockdown of EAAC1 expression (Sepkuty et al., 2002) , arguing that this modulation is not limited to the slice preparation. Manipulations of glutamate uptake exerted their effects on GABA release quickly and independently of synaptic activity, suggesting that presynaptic modulation of quantal size does not require vesicle release and recycling and that inhibition may be regulated rapidly. Reducing glutamate transport or GABA synthesis reduced mIPSC amplitudes only partially, however, indicating that other sources of GABA (e.g., reuptake) maintain the majority of the synaptic pool of transmitter. The primary role of glutamate transporters on inhibitory terminals, then, may be to strengthen inhibitory synapses in response to local increases in extracellular glutamate.
Neuronal glutamate transporters provide a substrate for GABA synthesis Although astrocytic glutamate transporters (GLT-1 and GLAST) mediate the large majority of uptake in brain tissue (Rothstein et al., 1996; Tanaka et al., 1997; Diamond and Jahr, 2000) , evidence also suggests that glutamate is taken up directly into nerve terminals (Gundersen et al., 1993; Danbolt, 2001) . EAAC1 is expressed at inhibitory presynaptic terminals (Rothstein et al., 1994; He et al., 2000) , where it could supply a substrate for GABA synthesis (Rothstein et al., 1994) . In vivo studies demonstrate that infusion of EAAC1 antisense oligonucleotides into rat brain reduces both GABA content and de novo GABA synthesis in the hippocampus (Sepkuty et al., 2002) . Because no selective inhibitor for EAAC1 exists, its physiological role in inhibitory transmission has been difficult to determine. THA and TBOA inhibit uptake by all of the transporter subtypes, whereas DHK (at the concentration used here) blocks only GLT-1. Together with the biochemical and anatomical studies mentioned above, our results showing that THA but not DHK reduces the synaptic GABA pool suggest that uptake into inhibitory terminals is mediated by EAAC1 or a transporter with similar pharmacology.
Glutamate taken up by astrocytes is converted by glutamine synthetase into glutamine, which is released and taken up into axon terminals, most likely by system A transporters (Chaudhry et al., 2002) . In neurons, glutamate is produced from glutamine by phosphate-activated glutaminase (PAG). Some GABAergic neurons express PAG (Manns et al., 2001) , whereas others do not (Kaneko and Mizuno, 1994) , and it is unclear whether GABAergic neurons use this pathway to produce glutamate for GABA synthesis. Several of our findings argue against the possibility that THA indirectly reduced the supply of glutamate to inhibitory neurons by inhibiting astrocytic uptake. First, the glutamine synthetase inhibitor MSO, which disrupts astrocytic glutamate metabolism (Laake et al., 1995) and the supply of glutamine to presynaptic terminals (Rothstein and Tabakoff, 1984; Laake et al., 1995) , did not diminish the effect of THA. Second, although in rats at this age, DHK and THA, at the concentrations used, exert comparable effects on glial transporter currents (Bergles and Jahr, 1997), DHK did not reduce mIPSC amplitudes (Fig. 6) . The increase in mIPSC amplitudes in the presence of DHK argues that blocking astrocytic uptake led to higher glutamate concentrations near inhibitory terminals (Muñoz et al., 1987) , thereby increasing neuronal uptake and GABA synthesis, in agreement with biochemical studies (Sepkuty et al., 2002) . Although it is possible that glutamine may serve as a precursor for glutamate in inhibitory terminals, it does not appear to mediate the effects of glutamate transporter antagonists described here.
Inhibiting GAD with MPA reduced mIPSC amplitudes, but even prolonged incubation in MPA did not completely deplete GABA in synaptic terminals. The lack of detectable GABA levels in GAD 65/67 double knock-out mice (Ji et al., 1999) indicates that nearly all GABA is synthesized by GAD; the incomplete effects of MPA suggest that, once synthesized, GABA is recycled effectively for an extended period, presumably by GABA reuptake.
Vesicular GABA content is dynamically regulated
We have shown that the GABA content of vesicles is downregulated or upregulated by glutamate uptake in a way that is linked to GABA synthesis, and that incompletely filled vesicles, or "overfilled" vesicles, can be released. This is in agreement with studies showing that modulation of vesicular content can increase or decrease miniature postsynaptic event amplitudes (Song et al., 1997; Williams, 1997; Zhou et al., 2000) . Enhancing glutamate uptake increased mIPSC amplitudes (Fig. 5) , suggesting that CA1 synapses normally may not be saturated by synaptically released transmitter (Hajos et al., 2000) . Our results showing that the releasable pool of synaptic vesicles did not have to be recycled Figure 6 . Presynaptic glutamate transporters do not exhibit GLT-1 pharmacology. A, Addition of 300 M DHK (black symbols; n ϭ 1409 events), a selective GLT-1 blocker, increased mIPSC amplitudes compared with control ( gray symbols; n ϭ 1455 events). Inset, Average mIPSC waveforms from a representative cell in control solution (gray) and in the presence of DHK (black). B, After preincubation with MPA, 300 M DHK (black; n ϭ 1096 events) no longer increased mIPSC amplitudes compared with control (gray; n ϭ 790 events). Inset, Average mIPSC waveforms from a representative cell in control solution (gray) and in the presence of DHK (black). norm, Normalized.
before an effect of THA was observed (Fig. 1C) support the view that the vesicular transmitter concentration reflects an equilibrium between the vesicle lumen and the terminal cytoplasm (Williams, 1997) . As a result, changes in GABA synthetic rate may be expressed very quickly in the vesicular transmitter concentration.
In light of these conclusions, it is surprising that we were unable to wash out the effects of THA on inhibitory synaptic responses, and, although glutamate-induced increases in mIPSC amplitude usually recovered, subsequent glutamate applications caused inconsistent results (data not shown). Modulating the extent of glutamate uptake may cause secondary metabolic effects that recover much more slowly. Such actions, however, may be specific to inhibitory terminals; the effects of transporter blockade on glutamatergic synaptic responses in astrocytes and pyramidal cells appear to wash out more readily (e.g., Bergles and Jahr, 1997; Diamond, 2001) .
A new protective role for glutamate transporters
The broad clinical utility of benzodiazapines, which exert only modest effects on GABAergic transmission (Perrais and Ropert, 2000) , indicates that even small changes in inhibitory strength have a significant physiological impact. Data reported here and elsewhere (Sepkuty et al., 2002) suggest that suppression of neuronal transporters, perhaps by modulatory proteins (Lin et al., 2001) , could reduce inhibition. Our results showing that exogenous glutamate enhances mIPSCs by way of neuronal transporters (Fig. 5) argue that glutamate uptake into inhibitory terminals may function as a mechanism to upregulate inhibition under certain conditions. For example, transient increases in extracellular glutamate levels that occur during hypoxia or seizures (for review, see Danbolt, 2001 ) may result in a compensatory or protective increase in inhibitory synaptic strength.
It also seems probable that such modulation occurs even in nonpathological conditions: Knockdown of EAAC1 expression in rats with antisense DNA induces epilepsy (Rothstein et al., 1996; Sepkuty et al., 2002) . This may indicate that the loss of the protective mechanism proposed here may itself be epileptogenic, although EAAC1 also may limit excitability in other ways (Diamond, 2001) . Evidence from human studies indicates that extracellular glutamate rises in the hippocampus before seizure onset (During and Spencer, 1993) . If this were generally true in epilepsy, then glutamate transporters could play an important role in preventing seizures. In addition to changes in extracellular glutamate, changes in the surface expression and capacity of transporters on terminals could play a role in regulating inhibitory synapses.
